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Induced osteogenic differentiation 
of human smooth muscle cells as a 
model of vascular calcification
Wera pustlauk1,2,3,4, Timm H. Westhoff4, Luc claeys5, Toralf Roch1,4,6, Sven Geißler1,2,6* & 
Nina Babel1,4,6
Vascular calcification is a severe pathological event in the manifestation of atherosclerosis. Pathogenic 
triggers mediating osteogenic differentiation of arterial smooth muscle cells (SMC) in humans remain 
insufficiently understood and are to a large extent investigated in animal models or cells derived 
thereof. Here, we describe an in vitro model based on SMC derived from healthy and diseased humans 
that allows to comprehensively investigate vascular calcification mechanisms. Comparing the impact 
of the commonly used SMC culture media VascuLife, DMEM, and M199, cells were characterised by 
immunofluorescence, flow cytometry, qPCR, and regarding their contractility and proliferative capacity. 
Irrespective of the arterial origin, the clinical background and the expansion medium used, all cells 
expressed typical molecular SMC marker while contractility varied between donors. Interestingly, the 
ability to induce an osteogenic differentiation strongly depended on the culture medium, with only 
SMC cultured in DMEM depositing calcified matrix upon osteogenic stimulation, which correlated 
with increased alkaline phosphatase activity, increased inorganic phosphate level and upregulation 
of osteogenic gene markers. Our optimized model is suitable for donor-oriented as well as broader 
screening of potential pathogenic mediators triggering vascular calcification. Translational studies 
aiming to identify and to evaluate therapeutic targets in a personalized fashion would be feasible.
Vascular calcification due to osteogenic differentiation of arterial smooth muscle cells (SMC) is a severe patho-
logical event in atherosclerosis. Massive, bone-like or brittle, amorphous calcifications can occlude the lumen, 
cause atherosclerotic plaque rupture, thrombus formation and infarction or result in failure of the arterial wall1–6. 
Deposition of calcified matrix within the vessel wall was described as an active, SMC-driven process5,7. This pro-
cess is initially marked by the switch of SMC from their contractile phenotype towards a synthetic state, in which 
proliferation and migration is enhanced8–12. The ability of SMC for phenotypic switching1,9 is important during 
vascular repair, but makes them also susceptible to pathological changes8,9,12–14, including their differentiation 
into osteoblast- and chondrocyte-like cells or acquisition of macrophage and foam cell markers1,11,13–22.
Several studies investigated the processes and key factors involved in the osteogenic differentiation of mam-
malian SMC, subsequent deposition of mineralized matrix and vascular calcification20,21,23–25. These studies pro-
vide evidence that an active inhibition of calcification and the prevention of pro-osteogenic gene expression is 
crucial for retention of the SMC phenotype7,23,26–28. Conversely, it was found that SMC-mediated calcification is 
enhanced by an inflammatory environment, oxidative stress, hypercalcaemia and hyperphosphatemia, as well as 
apoptosis, and senescence1,25,29–31. Despite the fact that these pathogenic triggers link atherosclerosis with other 
disorders like diabetes, chronic kidney disease, and osteoporosis, the specific mechanism underlying the osteo-
genic differentiation of SMC are still insufficiently understood1,7,32,33.
1Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, corporate 
member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 
2Julius Wolff Institute, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-
Universität zu Berlin, and Berlin Institute of Health, Berlin-Brandenburg Center for Regenerative Therapies, Berlin, 
Germany. 3Berlin-Brandenburg School for Regenerative Therapies, Charité - Universitätsmedizin Berlin, corporate 
member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 
4Center for Translational Medicine, Department of Internal Medicine I, Marien Hospital Herne, University Hospital 
of the Ruhr-University Bochum, Bochum, Germany. 5Department of Vascular Surgery, Marien Hospital Herne, 
University Hospital of the Ruhr-University Bochum, Bochum, Germany. 6These authors contributed equally: Toralf 
Roch, Sven Geißler and Nina Babel. *email: sven.geissler@charite.de
open
2Scientific RepoRtS |         (2020) 10:5951  | https://doi.org/10.1038/s41598-020-62568-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Since atherosclerosis and vascular calcification remain the leading cause of death worldwide there is a huge 
need to shift the research focus from the prevention of the disease towards late-stage intervention strategies for 
patients with already established disease and calcified plaques34. Considering this high medical demand and the 
often inadequate transferability of animal data to the clinically relevant human situation, especially innovative 
human in vitro models are needed. Studies of underlying disease mechanisms in the human context using bio-
logical material from the relevant patient cohorts will, furthermore, support the translation of the findings into 
clinical application. Such suitable human in vitro models require reproducible isolation and characterization of 
SMC from healthy and diseased arteries to enable the investigation of the pathological mechanism underlying 
SMC osteogenic transdifferentiation. Although, various in vitro approaches were used in previous studies, a com-
prehensive human model that includes systematic characterisation of SMC derived from healthy and diseased 
human donors is missing. Furthermore, systematically optimized culture conditions to investigate the osteo-
genic differentiation of SMC and a conclusive comparison of commonly used SMC culture media including their 
impact on the SMC phenotype is lacking.
Here, we established a human in vitro model of SMC calcification based on primary human SMC that allows 
to study the impact of potential mediators such as patient sera, immune cells, cytokines, drugs, or inhibitors on 
vascular calcification. We developed a protocol for the isolation of SMC derived from clinical samples of patients 
with various pathological alterations. The obtained SMC were analysed for their marker expression, contractility, 
proliferation, and osteogenic differentiation potential under different cell culture conditions. Our in depth evalu-
ation of SMC derived from six human donors demonstrates that this in vitro model with its comprehensive SMC 
characterisation and detailed analysis of the osteogenic differentiation process is suitable not only for the broad 
screening of potential pathogenic mediators triggering vascular calcification, but also for the identification of new 
therapeutic targets in a personalized fashion.
Results
Isolated cells display SMC characteristics irrespective of their arterial origin and clinical background. 
Primary cells isolated from various pathologically altered, clinical samples of different arterial origin were ana-
lysed with regard to their SMC phenotype as well as their SMC characteristics and compared to corresponding 
commercially available SMC isolated from healthy coronary arteries. Phase contrast images acquired at passage 
three showed a typical SMC morphology (Fig. 1). Cell identity was further confirmed by positive immunofluores-
cence staining for smooth muscle actin (SMA) and myosin heavy chain 11 (MYH11). No differences in SMA and 
MYH11 expression between healthy coronary artery SMC and cells derived from pathologically altered samples 
were observed. In addition, all SMC isolations were negative for the human skeletal muscle myoblast marker 
myosin heavy chain 4 (Supplementary Fig. S1). Thus, successful SMC isolation even from heavily calcified arter-
ies demonstrates suitability of the combined approach of tissue digestion and explant culture, irrespective of the 
clinical background, the arterial location, gender or patient age.
Isolated cells show SMC characteristics irrespective of the expansion medium used. For SMC 
isolation and expansion different culture media were used since a conclusive comparison of commonly described 
SMC culture media is lacking. To investigate the medium impact on SMC characteristics, marker expression of the 
cells was analysed after expansion in different media with 5 or 10% FCS as indicated in Table 1 and Supplementary 
Table S1. For flow cytometric surface marker analysis, single live cells were identified according to the gating 
strategy shown in Supplementary Fig. S2. Isolated cells were characterised as CD13+CD44+CD73+CD90+ and 
CD14−CD31−CD45− (Fig. 2a). However, donor-dependent variability was detected regarding the expression of 
CD31 (ID1, ID2), CD45 (ID2), and CD90 (ID4), illustrating plasticity. No distinct pattern could be determined 
for the expression of CD140b (Platelet-derived growth factor receptor β), with half of the donors being negative 
(ID1, ID2, ID4) while for the other half (ID3, ID5, ID6) a certain expression was detectable.
Gene expression analysis of SMC marker demonstrated comparable level of ACTA2, MYH11, MYOCD, 
TAGLN, PDGFRB, CNN1, and KCNMB1 expression in all isolated cells except those of ID5 (Fig. 2b). Overall, iso-
lated cells show common SMC characteristics irrespective of the expansion medium used and FCS concentration. 
Nevertheless, expression of SMC marker might be impacted by the expansion medium used as indicated by the 
lack of MYH11 and TAGLN expression in cells isolated from ID5 which were expanded in M199. Along the same 
lines was the increased CD31 expression in cells derived from ID1 and ID2 which were cultivated in VascuLife.
Contractility assessment indicates functional plasticity of SMC. To further examine SMC char-
acteristics, contractility of SMC was studied in a carbachol-based assay. Contraction of the isolated cells was 
induced by addition of carbachol to the expansion medium (Fig. 3a, Supplementary Movies a–f). To assess the 
impact of the medium, cells of ID3-6 were additionally tested after subcultivation in VascuLife medium for one 
passage (Fig. 3b, Supplementary Movies g–j). SMC derived from a healthy coronary artery (ID1) showed a dis-
tinct cell area reduction after 15 min while SMC derived from pathologically altered arteries showed no (ID3) 
or only slight contraction (ID2, ID4, ID6) in their respective expansion medium. Differences in contractility 
between the expansion medium and VascuLife medium could not be observed for ID3, ID4, and ID6, whereas 
an increased contractility after transfer to VascuLife medium was observed for ID5-derived SMC. Enhanced cell 
adhesion to the tissue culture plate in DMEM- and M199-based media might limit contractility of the SMC in 
vitro. Consequently, no distinct discrimination of SMC contractility depending on the expansion medium used 
could be determined. Collectively, functional assessment of SMC contractility illustrated donor-dependent dif-
ferences and highlighted SMC plasticity.
SMC proliferation varies between media. The proliferative capacity of the isolated cells expanded in 
different media was assessed to further determine donor-specific or medium-dependent differences. Except from 
3Scientific RepoRtS |         (2020) 10:5951  | https://doi.org/10.1038/s41598-020-62568-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
SMC of ID2, all cells showed progressive proliferation independent of the culture medium (Fig. 4). Cells derived 
from ID2 were restricted in their proliferative capacity even after three weeks in culture compared to the cells 
derived from the other donors (expansion medium control pictures of ID2 in Fig. 7b). While proliferation rates 
between SMC cultures with 10% FCS in DMEM and M199 media were largely comparable, increased prolifera-
tion rates were observed in cultures with 5% FCS and VascuLife medium.
Elevated alkaline phosphatase activity and phosphate level during osteogenic stimulation are 
indicative for an osteogenic differentiation of SMC. Since we found no direct dependence between 
the expansion medium used and the specific SMC characteristics, we wondered whether the culture medium 
affects the osteogenic differentiation potential of SMC. Therefore, SMC from each donor were osteogenically 
stimulated in their respective expansion medium supplemented with osteogenic additives. In addition, SMC 
were transferred to VascuLife and DMEM for osteogenic stimulation and corresponding expansion medium 
controls (Table 2). All osteogenic media were equally supplemented with FCS and glutamine in order to exclude 
Figure 1. Donor characteristics, sample overview, and immunofluorescence characterisation of isolated SMC. 
Cells isolated from various pathologically altered, clinical samples of different arterial origin were analysed 
morphologically and by immunofluorescence staining of specific marker proteins to confirm their SMC 
characteristics at passage three. Nuclei (blue) were visualized with DAPI. SMA (red) - smooth muscle actin, and 








Table 1. Cultivation media used for SMC isolation and expansion. D - DMEM, M - M199, S - supplements 
(FGF, EGF, insulin, ascorbic acid), VL - VascuLife.
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an impact of these two factors on the osteogenic differentiation process. Alkaline phosphatase (ALP) activity, as 
an early indicator of osteogenic differentiation, was determined on day 0 (baseline) as well as day 4, 7, and 10 of 
the osteogenic stimulation. A constant increase in all three osteogenic differentiation media tested was detected 
(Fig. 5a) compared to the expansion medium controls (Supplementary Fig. S3a). Induction of ALP activity was 
slightly stronger after osteogenic stimulation in DMEM compared to VascuLife and comparable in DMEM and 
M199. Irrespective of the osteogenic medium used, ALP activity varied between donors, with ID1, ID2, and ID3 
showing a strong upregulation while ALP activity remained weak until day ten in SMC cultures from ID4, ID5, 
and ID6. Interestingly, baseline ALP activity at day zero was especially high in SMC derived from a healthy cor-
onary artery (ID1), upregulation of its activity plateaued at day seven. In contrast, SMC derived from pathologi-
cally altered arteries of different arterial origin (ID2-6) showed lower baseline ALP activity and its upregulation 
did not reach a plateau until day ten.
Figure 2. SMC marker expression after expansion in different media. (a) Histograms of flow cytometric surface 
marker expression (grey) of CD13, CD14, CD31, CD44, CD45, CD73, CD90, and CD140b on single live cells 
at passage three or four identified according to the gating strategy shown in Supplementary Fig. S2. Marker 
expression is given in comparison to the unstained control (white). (b) Gene expression level of SMC marker in 
isolated cells at passage one or two, normalized to the expression of the housekeeping gene RPL13A. Values of 
the individual donors are shown as points superimposed onto the boxplots. Expansion medium of each donor is 
given in brackets; D - DMEM, M - M199, S - supplements (FGF, EGF, insulin, ascorbic acid), VL - VascuLife.
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In addition to the ALP activity, the concentration of its direct metabolite phosphate (PO4), was determined 
in the supernatant throughout the differentiation process. The increase of ALP activity in all osteogenically 
stimulated SMC correlated with an increase of PO4 (Fig. 5b) compared to the expansion medium controls 
(Supplementary Fig. S3b). Elevated ALP activity of SMC osteogenically stimulated in DMEM correlated with 
higher phosphate level in these cultures compared to corresponding cultures in VascuLife. Although ALP activ-
ity of osteogenically stimulated SMC was comparable in DMEM and M199, phosphate level remained lower in 
M199-stimulated cultures from day 14 onwards. In line with the elevated ALP activity in osteogenically stimu-
lated SMC derived from a healthy coronary artery (ID1), PO4 level were distinctly increased compared to SMC 
cultures derived from pathologically altered arteries (ID2-6). Regardless of the osteogenic differentiation medium 
used and the induced ALP activity, SMC from pathologically altered arteries (ID2-6) showed an early and sharp 
increase in phosphate levels within the first four days and remained at that plateau thereafter. In contrast, phos-
phate levels of SMC cultures derived from a healthy coronary artery (ID1) increased until day 14, before reaching 
a plateau. For the differentiation of these SMC in DMEM, a distinct drop of the phosphate level was observed after 
day 14, indicating enhanced deposition of calcium-phosphate matrix and thus withdrawal of phosphate from 
the supernatant. An early and ongoing decrease in phosphate level after osteogenic stimulation in DMEM was 
also noted for SMC from ID4. Taken together, elevated ALP activity during osteogenic stimulation indicated an 
osteogenic differentiation of SMC in all media tested, but is most distinct after osteogenic stimulation in DMEM. 
Upregulation of ALP activity resulted in elevated phosphate level while a decrease of the latter seems to correlate 
with calcification of SMC in vitro.
Increased gene expression of osteogenic markers substantiates an osteogenic differentiation 
while SMC characteristics are partially maintained. To further investigate the osteogenic differen-
tiation in SMC, expression of surrogate marker genes for the osteogenic differentiation, negative regulation of 
calcification and SMC lineage were analysed at day ten of the osteogenic stimulation and compared to base-
line level at day zero. A distinct increase of ALPL and the pro-osteogenic transcription factor RUNX2 could be 
observed for all SMC after ten days of osteogenic stimulation in all media tested (Fig. 6a, Supplementary Fig. S4a) 
compared to the respective expansion medium controls (EM vs. OM: ALPL (VL) p = 0.006; ALPL (D) p = 0.048; 
RUNX2 (VL) p = 0.037; RUNX2 (D) p = 0.019; for osteogenic stimulation in M199 no statistical analysis was pos-
sible). For COL1A2 a marked increase was only detected after osteogenic stimulation in VascuLife (EM vs. OM: 
COL1A2 (VL) p = 0.016) and M199 whereas only a slight upregulation was seen after osteogenic stimulation in 
DMEM. However, cultivation in DMEM already increased the constitutive expression of COL1A2 as detected in 
Figure 3. Contractility of SMC varies between donors. SMC expanded in different media were functionally 
assessed by stimulation with 10 µM carbachol for 15 min in (a) their respective expansion medium (given in 
brackets) or (b) after subcultivation in VascuLife medium for one passage. For visualization of stimulation-
induced cell area change the membrane of single cells was marked; D - DMEM, M - M199, S - supplements 
(FGF, EGF, insulin, ascorbic acid), VL - VascuLife.
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the expansion medium controls (Fig. 6a, Supplementary Fig. S4a). This general increase in COL1A2 expression 
might favour deposition of calcified matrix.
Independent from the culture medium, expression of MGP, a calcification inhibitor that prevents min-
eral precipitation in the extracellular matrix35, was markedly increased after osteogenic stimulation (Fig. 6b, 
Supplementary Fig. S4b). In contrast, expression of SPP1, an inhibitor of ectopic calcification35, remained weak 
in all osteogenically stimulated cultures and expansion medium controls. Except for the cultures of ID1 and ID6, 
expression was slightly downregulated during the osteogenic differentiation process of SMC.
In line with the increased expression of osteogenic markers krüppel-like factor 4 (KLF4), a stem cell factor and 
transcriptional repressor of SMC specific genes36, is slightly increased in osteogenically stimulated SMC while MYOCD, 
a transcription factor promoting the SMC lineage9, is downregulated (Fig. 6c, Supplementary Fig. S4c). Interestingly, 
ACTA2, characteristic for the SMC phenotype, was upregulated in correlation to the osteogenic markers (EM vs. OM: 
ACTA2 (VL) p = 0.001; Fig. 6c, Supplementary Fig. S4c). Collectively, gene expression analysis of osteogenic markers 
further confirmed an osteogenic differentiation while SMC characteristics are partially maintained.
SMC deposit calcified matrix only after osteogenic stimulation in DMEM. To confirm the osteo-
genic differentiation of SMC in different cultivation media, deposition of calcified matrix was analysed by alizarin 
red staining. After 21 days deposition of calcified matrix could only be detected in those cultures osteogeni-
cally stimulated in DMEM (Fig. 7a,b, Supplementary Fig. S5a,b). This effect was independent of the expansion 
Figure 4. Proliferation of SMC varies between expansion media. SMC of passage three were seeded at 2 × 103 
cells/well and expanded in different media. Cell proliferation was determined at the indicated time points using 
the CyQuant Proliferation assay and is shown as the fold change to day zero; D - DMEM, M - M199,  
S - supplements (FGF, EGF, insulin, ascorbic acid), VL - VascuLife.
Figure 5. Osteogenic stimulation elevates alkaline phosphatase activity and phosphate level indicating an 
osteogenic differentiation of SMC. (a) Alkaline phosphatase (ALP) activity after osteogenic stimulation of SMC 
in VascuLife, DMEM, or M199. ALP activity was normalized to the metabolic activity of the cells determined 
with PrestoBlue Cell Viability Reagent. (b) Phosphate (PO4) level determined in the supernatant of SMC 
osteogenically stimulated in VascuLife, DMEM, or M199. ALP and PO4 values are given as mean of five 
replicate wells per donor and medium ± standard deviation; D - DMEM, M - M199, S - supplements (FGF, EGF, 
insulin, ascorbic acid), VL - VascuLife.
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medium used before differentiation in DMEM. Nevertheless, conditioning effects of the expansion medium 
seem to impair the osteogenic differentiation in DMEM as shown for SMC of ID5 and ID6, both expanded in 
M199-based medium. Quantification of the deposited calcified matrix normalized to the cell number confirmed 
the significant difference between the osteogenic media tested (OM (D) vs. OM (VL) after 21 days of osteogenic 
stimulation: p = 0.013; Fig. 7c, Supplementary Fig. S5c).
Staining intensity and differences in the quantified amount of deposited calcified matrix depict 
donor-dependent differences in calcification onset and capacity (Fig. 7b,c, Supplementary Fig. S5b,c) with SMC 
derived from a healthy coronary artery (ID1) and SMC derived from a carotis stenosis (ID4) showing distinct 
deposition of calcified matrix already on day 14 of osteogenic stimulation in DMEM. SMC of ID4 even showed 
contraction of the cell layer and minor deposition of calcified matrix in the D+S expansion medium control, 
indicating a preosteoblastic imprint of these cells from the previous pathologic alterations in the A. carotis. For 
the donors ID1 and ID4 a drop or decrease in the supernatant phosphate level was noted that correlates with the 
amount of deposited calcified matrix (Fig. 6b). All other SMC started to deposit increasing amounts of calcified 
matrix only after day 14, suggesting the need of a prolonged osteogenic stimulus before a substantial osteogenic 
differentiation in those SMC is induced that results in deposition of calcified matrix. Overall, osteogenic differ-
entiation confirmed the potential of SMC to deposit calcified matrix, for this stimulation in DMEM is required.
Although only SMC cultures stimulated in DMEM deposited calcified matrix, proliferation and cell numbers 
were distinctly lower in all cultures with osteogenic media compared to their corresponding expansion medium 
controls (Supplementary Fig. S6), indicating successful induction of a switch from proliferation towards differen-
tiation. No significant differences in cell numbers between the different osteogenic media and expansion media 
controls or between day 14 and day 21 could be determined. However, SMC of ID3 show an increased prolif-
eration in response to the osteogenic stimulus. This is in line with an increased expression of the transcription 
factor MYOCD in these cultures on day 10 (Fig. 6c) whereas all other SMC cultures show a reduced expression of 
MYOCD under the osteogenic stimulus.
Discussion
In this study, we established and optimized a human in vitro model for the investigation of advanced atheroscle-
rosis and vascular calcification, based on SMC derived from healthy and diseased donors. The model allows to 
study late-stage intervention strategies for patients with already established disease and calcified plaques and thus 
addresses an increasing clinical need in aging societies. Although, in vitro cultivation of SMC might be limited 
in mimicking disease-relevant in vivo processes11,37,38, our model with its comprehensive work flow can be used 
to investigate donor-dependent differences of potential therapeutic relevance as well as broader screening for 
potential pathologic mediators causing vascular calcification (Fig. 8). Thus, being of advantage compared to ani-
mal models used in other studies.
Our comprehensive characterisation of the isolated SMC, together with the functional evaluation, considers 
SMC plasticity and thus adds weight to previously described in vitro models20,21,23–25. Furthermore, a systematic 
comparison of commonly described culture media optimizes the conditions to properly investigate the osteogenic 
differentiation potential of SMC, including potential pathogenic mediators. The combined approach of digestion 
and explant culture was feasible for the isolation of SMC from all patient-derived samples which were obtained 
from different arterial locations and had different degrees of calcification. Irrespective of the culture medium 
used and its FCS concentration all isolated cells exhibited an SMC-like phenotype. However, isolation protocols 
have to consider broadly described SMC plasticity1,9. In that regard, it has to be assumed that the obtained SMC 
are the more viable and migratory ones. Although, potential donor-dependent differences might have vanished 
as an effect of the isolation protocol and the culture conditions38, flow cytometric surface marker analysis char-
acterised all SMC as CD13+CD44+CD73+CD90+ and CD14−CD31−CD45−. Except for the expression of CD90, 
this marker pattern is in line with the study by Kumar et al. (2017) characterising SMC derived from human 
mesenchymoangioblast39. Of these, CD44 and CD90 were recently described as identifier for a relatively rare 
population of mesenchymal progenitor cells within the vessel wall40–42. However, except for SMC of ID4, derived 
from a carotis stenosis, all our SMC, including those from a healthy coronary artery, showed CD44 and CD90 
expression of the entire cell population. This suggests that both markers are commonly expressed by arterial SMC 






VL D D+S M M+S VL D M
ID1 x x x x
ID2 x x x x
ID3 x x x x
ID4 x x x x
ID5 x x x x x x
ID6 x x x x x x
Table 2. Osteogenic media and expansion medium controls used for comparison regarding the differentiation 
potential of SMC. EM - expansion medium; OM - osteogenic medium (EM with 50 µM ascorbic acid, 10 mM 
β-Glycerophosphate and 0.1 µM dexamethasone); D - DMEM, M - M199, S - supplements (FGF, EGF, insulin, 
ascorbic acid), VL - VascuLife.
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osteogenic differentiation of mesenchymal stromal cells was demonstrated recently43–45, its expression on SMC 
might also be of relevance considering their potential for osteogenic differentiation.
Further variability, highlighting donor-dependent differences and SMC plasticity, was observed for the expres-
sion of CD31, CD45, and CD140b. CD31 expression might be indicative of an immature SMC phenotype39. 
However, its induction seems to depend on the cultivation medium used, since only SMC cultivated in VascuLife 
showed a tendency to express CD31. Expression of CD45 in SMC derived from ID2 might indicate that those 
cells are descendants of an endothelial to mesenchymal transition occurred during lesion formation as described 
for mitral valve endothelial cells after myocardial infarction46. Variance concerning the expression of CD140b 
could only be observed when measured as surface protein, not in the gene expression analysis. This discrepancy 
might emerge from regulated trafficking of CD140b47 that seems to be of relevance during SMC recruitment to 
the fibrous cap14,48 and further illustrates SMC plasticity.
Moreover, isolated cells from pathologically altered arterial samples and SMC derived from a healthy coronary 
artery showed a similar expression of the SMC markers ACTA2, MYH11, MYOCD, TAGLN, PDGFRB, CNN1, 
and KCNMB1. This expression pattern characterises the cells as SMC, albeit, not all of these markers are consid-
ered as exclusive for the SMC lineage and expression might change due to phenotypic plasticity. Yet, expression of 
KCNMB1, a beta-1 subunit of calcium-activated potassium channels involved in vasoregulation, was shown to be 
restricted to vascular smooth muscle tissue49,50. Furthermore, MYH11 is considered as the most discriminating 
marker of the SMC lineage9,11, its detection in the immunofluorescence staining confirmed the SMC phenotype. 
Generally, only low expression levels of genes associated with contractility seem to be required to maintain a 
certain protein level in SMC, possibly reflecting the low turnover of contractile proteins38,51. Thus, low mRNA 
expression levels of MYH11, but distinct protein levels as assessed by immunofluorescence staining confirms the 
low turnover of this contractile protein even after passaging in vitro.
Besides the presence of contractile filaments, functional assessment of the isolated cells using a contraction 
assay highlighted SMC plasticity. Observed differences in contractility between SMC cultures derived from dif-
ferent donors might be dependent on the cytoskeleton arrangement possibly affected by the culture conditions. 
Earlier studies showed that in vitro cultivation of SMC could induce a phenotypic transition from a contractile 
phenotype towards a synthetic state with diminished contractility8–10. In that regard, diminished serum concen-
trations as in VascuLife medium seem to favour a contractile SMC phenotype by inhibiting modulation towards 
a proliferative state10. We observed no distinct difference in SMC ability to contract between the initial expansion 
medium or after subcultivation in VascuLife medium for one passage. Nevertheless, an impact of the medium 
used for cell isolation and initial expansion on contractility cannot be fully excluded in later passages, especially 
since medium-dependent differences in cell proliferation were observed that might limit contractility.
Overall, although the embryological origin of the SMC isolated in our study might vary according to the loca-
tion they are derived from52,53, we could not determine distinct differences of the SMC characteristics dependent 
on the location of sample removal, clinical background, or the expansion medium used. However, with regard 
to the subsequent osteogenic stimulation and the potential for deposition of calcified matrix, SMC expansion in 
either VascuLife or DMEM is recommended. Due to the limited number of donors in our study, broader screen-
ing with additional donors might be needed to enable further discrimination.
In line with the similar SMC characteristics determined, all SMC exhibited a similar osteogenic differentiation 
potential, irrespective of their arterial location and their embryological origin52,53. However, even after adjusting 
FCS and glutamine concentrations, the degree of osteogenic differentiation and deposition of calcified matrix was 
strongly dependent on the cultivation medium used, illustrating the importance of environmental cues for the 
behaviour of SMC9. Irrespective of the expansion medium used, differentiation including substantial deposition 
of calcified matrix was only observed after osteogenic stimulation in DMEM. Considering calcification onset and 
capacity, donor-dependent differences were notified, with some donors requiring a prolonged osteogenic stimu-
lus of 21 days until a substantial deposition of calcified matrix could be observed, whereas others showed substan-
tial matrix deposition already on day 14. A preosteoblastic imprint of SMC from ID4, reflected by contraction of 
the cell layer even in the expansion medium control, might have triggered an enhanced osteogenic differentiation 
in those SMC. Furthermore, decreased CD90 expression, as detected in SMC from this donor, might be indicative 
for a matured osteoblastic transition44,54. Enhanced osteogenic differentiation of SMC derived from a healthy 
coronary artery, might result from an increased susceptibility to in vitro stimulation. Since cells derived from a 
healthy donor are exposed to differentiation stimuli for the first time in our in vitro model, they seem to be more 
prone to respond to the stimulation compared to SMC derived from pathologically altered arteries. The latter 
might have adjusted to their previous disease state, thus requiring a prolonged stimulation in vitro to undergo 
further phenotypic modulation and differentiation.
In five out of six SMC cultures the observed osteogenic differentiation was accompanied by reduced pro-
liferation and cell numbers. Ongoing proliferation was only observed for SMC from ID3 and is in line with an 
increased MYOCD expression while all other SMC cultures showed a reduced expression of MYOCD under the 
osteogenic stimulus. Increased proliferation of SMC from ID3 might thus be driven by a sustained expression of 
the transcription factor MYOCD.
Besides the medium composition, calcium and phosphate levels are highly relevant for the in vitro calcifica-
tion of SMC. Increased calcium and phosphate concentrations were shown to induce SMC calcification, thus, 
their ratio should be considered during stimulation to avoid side effects from additional stimulation, e.g. ear-
lier calcification with elevated calcium level, and supplementary signalling1,29,55–58. In our approach all cultiva-
tion media have a similar calcium concentration while the basal phosphate concentration is slightly lower in 
VascuLife medium compared to DMEM and M199 (Supplementary Table S1). For the osteogenic stimulation 
media were supplemented with β-Glycerophosphate disodium salt hydrate, an organic phosphate donor that 
requires enzymatic activity of alkaline phosphatase to increase the extracellular phosphate concentration above 
baseline level. Such active cell involvement in the generation of inorganic phosphate occurs more suitable for the 
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study of triggers and mechanisms involved in the osteogenic differentiation of SMC than supplementing media 
with inorganic phosphate and calcium that could be disease-relevant triggers themselves55,56,59,60.
In our model increased ALP activity was reflected by increased ALPL gene expression. Together with an 
upregulated expression of the osteogenic markers RUNX2 and COL1A2 an osteogenic differentiation of the SMC 
was substantiated that is likely to be mediated by the induction of the stem cell factor and transcriptional repres-
sor of SMC specific genes KLF436. Parallel to the upregulation of osteogenic differentiation markers upon stim-
ulation and in line with an earlier in vitro study investigating calcification of human vascular cells61, expression 
of MGP, a negative regulator of mineral precipitation28,35, was markedly increased after ten days of osteogenic 
differentiation. Elevated MGP expression might be indicative for a counteracting strategy of the SMC while being 
Figure 6. Increased gene expression of osteogenic markers after stimulation in VascuLife and DMEM 
substantiates an osteogenic differentiation of SMC while SMC characteristics are partially maintained. Gene 
expression analysis of SMC osteogenically stimulated in VascuLife or DMEM for ten days; (a) osteogenic marker, 
(b) negative regulators of calcification, (c) SMC marker and transcriptional regulators. Expression was normalized 
to the expression of the housekeeping gene RPL13A and the fold change between day zero (baseline) and day 
ten was calculated. Expansion medium controls for DMEM and DMEM plus supplements were pooled for 
quantitative analysis. Gene expression analysis of ID2-derived SMC was not possible due to low cell numbers and 
resulting insufficient amounts of isolated mRNA. For statistical analysis a Kruskal-Wallis-test with an uncorrected 
Dunn’s post test was used. Only significant differences (p < 0.05) are given; D - DMEM, M - M199, S - supplements 
(FGF, EGF, insulin, ascorbic acid), VL - VascuLife, EM - expansion medium, OM - osteogenic medium.
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Figure 7. SMC deposit calcified matrix only after osteogenic stimulation in DMEM. Alizarin red staining of 
calcified matrix deposited by SMC osteogenically stimulated in different culture media for 14 and 21 days. (a) 
Macroscopic examination of calcified matrix deposition by SMC after 21 days of osteogenic stimulation in 
VascuLife or DMEM. (b) Microscopic examination of the wells and their respective expansion media controls 
after 21 days of osteogenic stimulation in VascuLife or DMEM. (c) Quantification of the deposited calcified 
matrix normalized to the cell number on day 14 and day 21. Expansion medium controls for DMEM and 
DMEM plus supplements were pooled for quantitative analysis. Values of the individual donors are shown as 
points superimposed onto the boxplots and are given as mean of five replicate wells per donor and medium. For 
statistical analysis data of each point in time were compared amongst each other using a Kruskal-Wallis-test 
with a Dunn’s post test corrected for multiple comparisons. Only significant differences (p < 0.05) are given; 
D - DMEM, S - supplements (FGF, EGF, insulin, ascorbic acid), VL - VascuLife, EM - expansion medium, OM - 
osteogenic medium.
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exposed to a sustained osteogenic stimulus. However, the synthesised MGP might be under-carboxylated and 
thus dysfunctional as mineralization inhibitor62. Compared to MGP, expression of SPP1, another known negative 
regulator of calcification35, remained weak. Such diminished gene expression and very low concentrations of 
secreted osteopontin protein in human SMC cultures were described earlier61. Although osteopontin is described 
to be an inducible inhibitor of vascular calcification in vivo63, SMC were shown not to be the predominant source 
during vascular calcification61. Considering the phenotypic switching and osteogenic differentiation of SMC, 
previous studies furthermore indicated that this process is accompanied by a loss of SMC markers like ACTA2, 
TAGLN, MYH11, and CNN11,20,36. Although MYOCD as a potent inducer of SMC marker genes9 is downregulated 
after osteogenic stimulation in all SMC cultures except those of ID3, we detected a distinct increase of ACTA2 
expression, indicating that despite an osteogenic differentiation the SMC phenotype is still partially maintained53. 
In contrast to the above mentioned studies, such co-expression of osteogenic and SMC marker was demonstrated 
earlier in vitro and ex vivo5,19,61. Increased expression of ACTA2 might thereby be induced upon growth arrest, e.g. 
at high cell densities64. However, the outlined contradictions will require further investigations.
Overall, our in depth study of SMC from six human donors highlights their phenotypic plasticity and their 
dependency on complex interactions of local environmental cues. In that regard, we could demonstrate that vas-
cular calcification in vitro is mimicked best by the osteogenic differentiation of SMC in DMEM. With our human 
SMC-based, disease-relevant in vitro model donor differences and disease-associated imprints can be detected 
that can be of relevance for personalized treatment. Furthermore, broader screening for potential pathogenic 
mediators that cause vascular calcification and, considering the 3R approach, translational oriented studies to 
identify and evaluate therapeutic targets are possible by addition of patient sera, cytokines, drugs, inhibitors or 
co-culture approaches.
Methods
Sample acquisition and ethics statement. Total endarterectomy samples of calcified arteries and aneu-
rysms (Fig. 1) from different arterial locations were obtained from the University Clinic Ruhr, Bochum, Germany 
according to the Declaration of Helsinki after ethical approval of the Ethics Committee, Medical Faculty of Ruhr-
University Bochum (Registration-Number: 16-5714, 07.07.2016). Samples were stored at 4 °C either in serum free 
Dulbecco’s Modified Eagle Medium low glucose (D5546; DMEM), M199 (M4530, both Sigma), Ringer’s solution 
(Fresenius) or Hank’s balanced salt solution with sodium bicarbonate, supplemented with 0.025 M HEPES (both 
Sigma) and 1% penicillin/streptomycin (Biochrom) until SMC isolation. Commercially available healthy coro-
nary artery SMC (Lifeline Cell Technology) were used for comparison.
SMC isolation and expansion. SMC were isolated combining digestion and explant culture. Samples were 
rinsed in phosphate buffered saline (PBS, Gibco) and remaining endothelium was scrapped off with a scalpel 
where possible. Heavily calcified areas, fat tissue, and adventitial remnants were removed to dissect intimal and 
medial fragments. Tissue fragments were rinsed again in PBS, minced, and enzymatically digested in 2 mg/ml 
collagenase I (Gibco) in serum-free medium for 3 to 4 hours until the tissue was well loosened. For isolation and 
expansion several cultivation media described as suitable for SMC cultures were compared. Accordingly, cell 
suspension and remaining tissue fragments were placed in cell culture flasks with either VascuLife SMC Medium 
(VL; CellSystems GmbH), a 5% FCS medium, DMEM (D) supplemented with 1% Glutamax (Invitrogen), or 
M199 (M), the latter two being further supplemented with 1% penicillin/streptomycin and 20% fetal calf serum 
(FCS; Biochrom) during passage zero or 10% FCS from passage one on. For additional comparison, DMEM and 
M199 were supplemented with the same additives as used in VascuLife SMC Medium, that is 50 µg/ml L-Ascorbic 
acid 2-phosphate sesquimagnesium salt hydrate, 5 µg/ml insulin (both Sigma-Aldrich), 5 ng/ml endothelial 
growth factor (EGF; BioLegend), and 5 ng/ml recombinant human fibroblast growth factor (FGF; PeproTech; 
DMEM plus supplements (D+S); M199 plus supplements (M+S)). An overview of the cultivation media com-
position is given in Supplementary Table S1. Sample size limited isolation and primary cell expansion to one cul-
tivation medium per donor (Table 1). Medium was exchanged one day post seeding and twice a week thereafter. 
Cells were cultivated until near confluency; tissue fragments remained in the flask until the end of passage zero.
Figure 8. Schematic work flow for the in vitro analysis of vascular calcification.
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Immunofluorescence. SMC of passage three and human skeletal muscle myoblasts (Lonza) were grown 
in 96-well plates (Falcon), fixated with Roti-Histofix 4% (Roth), permeabilized with 0.2% Triton X-100 (Sigma) 
in PBS, and blocked with 1% bovine serum albumin (BSA; Sigma) and 5% normal goat serum (NGS; Vector 
Laboratories) in PBS. Each step was performed for 10 min. Antibodies and dilutions used for staining are 
summarized in Table 3. Cells were incubated over night at 4 °C with the respective primary antibody diluted 
in PBS with 1% BSA. The secondary antibody was diluted in PBS with 2% BSA and 2% NGS and cells were 
incubated for 1 h at room temperature. Nuclei were visualized with 1 µg/ml 4′,6-Diamidin-2-phenylindol 
(DAPI; Sigma) diluted in PBS for 10 min at room temperature. Images of immunolabelled cells were acquired 
using a Leica DMI 6000B with a 20× HCX PL FLUOTAR objective, equipped with a Leica DFC345 FX cam-
era and the imaging software Leica Application Suite V2.5.0.6735 (Leica Microsystems CMS GmbH).
Quantitative real-time PCR. For gene expression analysis, mRNA was isolated using the RNeasy Plus 
mini kit (Qiagen) and mRNA concentration was determined using a NanoDrop ND-1000 spectrophotometer 
(PeqLab). 250 ng mRNA were reverse transcribed to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad). 
Quantitative real-time PCR (qRT-PCR) was performed using the SYBR Green PCR master mix (Roche) and the 
primer pairs summarized in Table 4. Reactions were run on a LightCycler 480 II (Roche). For SMC characterisa-
tion cells at passage one or two were used and relative expression levels were calculated by normalizing minimal 
cycle threshold values (Ct) to the respective expression of the housekeeping gene RPL13A. To analyse the gene 
expression during osteogenic differentiation the fold change of each gene of interest was calculated, comparing 
the expression at day ten in the respective differentiation medium to the expression at day zero in the respective 
expansion medium of each donor. No mRNA analysis during osteogenic differentiation of SMC from ID2 was 
possible due to insufficient cell numbers.
Flow cytometry analysis. Single cell suspensions of passage three or four were prepared using 0.05% 
Trypsin-EDTA (Gibco). To avoid unspecific antibody binding to Fc receptors (FcR), cells were blocked with 
FcR Blocking Reagent (Miltenyi Biotech) according to the manufacturer’s instruction. Cell surface marker were 
stained for 10 min using the antibodies and dilutions given in Table 3. LIVE/DEADTM Fixable Blue Dead Cell 
Stain Kit (Invitrogen) was used to exclude dead cells. Cells were acquired using a CytoFLEX LX flow cytometer 
(Beckman Coulter). Flow cytometric data were analysed with FlowJo V10 (FlowJo, LLC).
Contraction assay. SMC cultures were stimulated with 10 µM carbachol (Sigma) in their respective expan-
sion medium. To further assess the medium impact on cell contractility, cells of ID3-6 were additionally trans-
ferred to VascuLife medium for one passage before being stimulated with carbachol in this medium. Time lapse 
images were recorded for 15 min at 37 °C and 5% CO2 using a Leica DMI 6000B equipped with a Leica DFC345 
FX camera and a BL-X incubator (Leica Microsystems CMS GmbH). Images were acquired using a 5× or 10× 
HCX PL FLUOTAR objective and the imaging software Leica Application Suite V2.5.0.6735. Time lapse serial 
images were converted to QuickTime movies and the membrane of single cells was marked for visualization of 
stimulation-induced cell area change using ImageJ software (NIH).
Antibody target Clone Conjugate Dilution Application Company
Catalogue number 
(Lot)
Anti-human SMA 1A4 PE 1/50 IF R&D Systems IC1420P(B174246)
Anti-human MYH4 MF20 — 1/250 IF eBioscience 14-6503-82(CAEI0818101)
Anti-human MYH11 1G12 — 1/100 IF Abcam ab683(GR273859-7)
Goat anti-mouse IgG 


































CD140b 28D4 PerCP/Cy5.5 1/50 FC BD Pharmingen
562714
(7083965 & 722771)
Table 3. List of antibodies used for SMC immunofluorescence and flow cytometry. If not stated otherwise, all 
antibodies are monoclonal; IF - immunofluorescence, FC - flow cytometry.
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Proliferation assay. SMC at passage three were seeded in 96-well plates with 2 × 103 cells/well and 64 µl 
medium/well; five replicate wells per donor and expansion medium were seeded. To compare medium effects on 
cell proliferation, 24 h post-seeding (baseline day zero) expansion medium of each SMC culture was replaced by 
the expansion media given in Table 2. On day zero, three, seven, and ten wells were washed with PBS and stored 
empty at −80 °C until further analysis. Cell count was determined using the CyQuant proliferation assay. The fold 
change to day zero was calculated for each time point and cell numbers are given as mean of five replicate wells 
per donor and medium ± standard deviation.
Osteogenic differentiation of SMC. Osteogenic differentiation of SMC at passage four was performed in 
96-well plates with 2 × 103 cells/well and 64 µl medium/well; five replicate wells per donor and expansion medium 
control or osteogenic stimulation were seeded. For mRNA isolation SMC were seeded in 6-well plates with 6×104 
cells/well and 2 ml medium/well; three replicate wells per donor and expansion medium control or osteogenic 
stimulation were pooled for mRNA isolation. All SMC were seeded in their respective expansion medium.
24 h post-seeding, osteogenic differentiation of SMC was induced. To assess the medium impact on their dif-
ferentiation potential, SMC from each donor were on the one hand osteogenically stimulated in their respective 
expansion medium while, on the other hand, expansion and osteogenic medium (EM; OM) were changed to either 
VascuLife or DMEM (Table 2). For the osteogenic differentiation each medium was equally supplemented with 
10% FCS, 1% Glutamax and 1% penicillin/streptomycin, 50 µM L-Ascorbic acid 2-phosphate sesquimagnesium salt 
hydrate, 10 mM β-Glycerophosphate disodium salt hydrate and 0.1 µM water soluble dexamethasone (the last three 
all Sigma-Aldrich) according to a standard protocol used for the differentiation of mesenchymal stromal cells65. 
SMC were osteogenically stimulated for 21 days, with medium exchange every 3 to 4 days. Cell culture supernatant 
was collected for phosphate analysis at each medium exchange and stored at −80 °C until further analysis.
Evaluation of metabolic activity. Metabolic activity of the cells was assessed using the PrestoBlue Cell 
Viability Reagent (Invitrogen). Ten volumes of pre-warmed expansion medium were mixed with one volume of 
PrestoBlue Cell Viability Reagent. Cells stimulated in 96-well plates were incubated with 64 µl of this mixture for 
1 h at 37 °C and 5% CO2. Absorption at 590 nm was measured using an infinite M200PRO plate reader (Tecan); 
blank values were subtracted.
Gene
Abbre-
viation Direction Sequences 5′ → 3′ Reference ID

























































Table 4. List of primers used for qRT-PCR. Primer were designed using NCBI Primer-BLAST or primers from 
the Harvard PrimerBank (pga.mgh.harvard.edu/primerbank) were used; respective reference IDs are given for 
the latter.
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Evaluation of alkaline phosphatase activity. The enzymatic activity of alkaline phosphatase (ALP) was 
assessed at day 0, 4, 7, and 10 by its turnover of para-nitrophenyl phosphate disodium hexahydrate (pNPP; Sigma) 
as described previously66. The volume of all solutions was adjusted as follows. Wells were rinsed with 150 µl PBS, 
followed by a wash with 200 µl AP-buffer. SMC were then incubated with 100 µl of pNPP substrate mixed 1:1 with 
AP-buffer for 10 min at 37 °C and 5% CO2, the reaction was terminated by addition of an equal volume of 1 M 
sodium hydroxide solution (Sigma). 100 µl were transferred to a 96-well plate and absorption was measured at 
405 nm using an infinite M200PRO plate reader. Calculated ALP activity was normalized to the prior determined 
metabolic activity of the cells and is given as mean of five replicate wells per donor and medium control ± stand-
ard deviation.
Phosphate assay. Phosphate (PO4) concentrations were determined in the supernatant of each well for 
each media exchange using the Phosphate Assay Kit (Abcam) according to the manufacturer’s instructions. 
Absorbance was measured at 650 nm using an infinite M200PRO plate reader; blank values were subtracted. 
Values are given as mean of five replicate wells per donor and expansion medium control or osteogenic stimula-
tion ± standard deviation.
Alizarin red staining. Osteogenic differentiation and deposition of calcified matrix was determined by aliz-
arin red staining at day 14 and day 21. For this, osteogenically differentiated and expansion medium control SMC 
cultivated in 96-well plates were fixated with Roti-Histofix 4% after evaluation of the metabolic activity. Prior to 
alizarin red staining cells were stained with 10 µg/ml Hoechst (Sigma) diluted in PBS for 10 min for quantifica-
tion of the cell number. Hoechst staining per well was determined at 460 nm using an infinite M200PRO plate 
reader. Subsequently, wells were stained with 75 µl 0.5% alizarin red S (Sigma; in ddH2O, pH 4.2) for 10 min at 
room temperature. Wells were washed three times with ddH2O to remove unbound dye, further washing steps 
were added if needed. Plates were allowed to dry and staining was documented macroscopically using an IXU185 
camera (Canon) as well as microscopically using a Leica DMIL LED with a 5× N PLAN PHO objective, equipped 
with a Leica DFC345 FX camera and the imaging software Leica Application Suite V3.7. Alizarin red staining of 
the deposited calcified matrix was quantified by absorption at 562 nm using an infinite M200PRO plate reader, 
following elution with cetylpyridinium chloride (Sigma; 10% solution in ddH2O). Blank values of cetylpyridin-
ium chloride were subtracted and alizarin red values were normalized to the cell number determined by Hoechst 
staining. Values are given as mean of five replicate wells per donor and medium. To analyse the medium impact 
on the osteogenic differentiation of SMC, means of the quantified alizarin red values were calculated for each 
osteogenic differentiation medium used. Expansion medium controls of DMEM and DMEM plus supplements 
as well as M199 and M199 plus supplements were pooled for this quantitative analysis.
Statistical analysis. For graphical representation, fold change calculation, and statistical analysis GraphPad 
Prism V8.0.0 was used. Data of each donor are expressed as mean of five replicate wells ± standard deviation. 
Boxplots represent the 25th, 50th, and 75th percentile and whiskers represent the range of the observations. 
Each point signifies a single donor. Data were analysed for normal distribution using a Shapiro-Wilk test. Due 
to outliers normal distribution could not be confirmed for all data sets tested, thus, for statistical comparison 
non-parametric testing was applied. For comparison of experimental groups during each point in time of the 
osteogenic differentiation in VascuLife and DMEM stained with alizarin red and for the related cell numbers 
determined by nuclei staining with HOECHST an unpaired Kruskal-Wallis-test with a Dunn’s post test corrected 
for multiple comparisons was used. For the exploratory gene expression analysis an uncorrected Dunn’s post test 
was applied. Level of significance were set at p < 0.05. No statistical analysis was possible for SMC osteogenically 
stimulated in M199 due to the limited number of experimental groups.
Data availability
All data generated or analysed during this study are included in this published article and its Supplementary 
Information Files.
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